Evidence map›Paper›PMID 42022351›Full record

ArticlePrecision radiation oncology2026

Sodium glycididazole combined with definitive chemoradiotherapy for patients with esophageal squamous cell carcinoma: A multicenter randomized clinical trial.

Xiaoling Li, Hanxi Zhao, Peng Xie, Wanqi Zhu, Liping Liu, Peipei Wu, Yanxing Sheng, Chuandong Wang, Yipeng Song, Xiangjiao Meng and 2 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Precision radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02721563 (A Perspective Random Trial of Sodium Glycididazole Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced Squamous Cell Esophageal Carcinoma), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02721563 phase4completednot on this map

A Perspective Random Trial of Sodium Glycididazole Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced Squamous Cell Esophageal Carcinoma

TypeinterventionalSponsorShandong Cancer Hospital and InstituteRan2016 to 2018Enrolled77ConditionsEsophageal NeoplasmsArmsSodium Glycididazole, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xiaoling LiDepartment of Radiation Oncology Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences Jinan Shandong China.ORCID https://orcid.org/0000-0001-8418-6233
Hanxi ZhaoDepartment of Radiation Oncology Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences Jinan Shandong China.
Peng XieDepartment of Radiology Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences Jinan Shandong China.ORCID https://orcid.org/0000-0002-7235-3230
Wanqi ZhuDepartment of Pathology Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences Jinan Shandong China.
Liping LiuDepartment of Radiation Oncology Jining No.1 People's Hospital Jining Shandong China.
Peipei WuDepartment of Radiation Oncology Jining No.1 People's Hospital Jining Shandong China.
Yanxing ShengDepartment of Radiation Oncology Liaocheng People's Hospital Liaocheng Shandong China.
Chuandong WangDepartment of Radiation Oncology Anqiu People's Hospital Anqiu Shandong China.
Yipeng SongDepartment of Radiation Oncology Yantai Yuhuangding Hospital Yan Tai Shandong China.
Xiangjiao MengDepartment of Radiation Oncology Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences Jinan Shandong China.ORCID https://orcid.org/0000-0003-2737-5905
Jiandong ZhangDepartment of Radiation Oncology The First Affiliated Hospial of Shandong First Medical Universit Shandong Province Qianfoshan Hospital Jinan Shandong China.
Ligang XingDepartment of Radiation Oncology Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences Jinan Shandong China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To evaluate the efficacy and safety of the radiosensitizer-sodium glycididazole (CMNa) combined with definitive concurrent chemoradiotherapy (CCRT) versus CCRT alone in patients with locally advanced esophageal squamous cell carcinoma (ESCC). Methods: Patients were enrolled and randomly assigned to receive CMNa plus CCRT (CMNa group) or CCRT alone (control group). CMNa (800 mg/m Results: Sixty-six patients with ESCC were recruited from six medical centers between 2016 and 2018. The ORRs in the CMNa and control groups were 90.32% and 68.57%, respectively ( Conclusion: CMNa combined with CCRT improved the ORR in patients with ESCC compared with CCRT alone without increasing treatment-related toxicity. Trial Registration: The protocol was registered at Clinicaltrials.gov (www.clinicaltrials.gov) (Clinical Trials ID: NCT02721563). Study Registration Date: March 29, 2016.

Indexed as

concurrent chemoradiotherapyesophageal squamous cell carcinomasodium glycididazole

Identifiers

PMID42022351
PMCPMC13097628

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.